LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

LLY

922.4

-0.08%↓

UNH

589.22

-0.85%↓

NVO

137.37

+0.29%↑

JNJ

166.55

+0.63%↑

ABBV

195.28

+0.62%↑

Inicio・Lista de Acciones・Nektar Therapeutics

Nektar Therapeutics

Abierto

1.25 -3.85

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.23

Máximo

1.3

Métricas clave
By Trading Economics
Ingresos	-46M
Ventas	-259K 24M
BPA	-0.22
Margen de beneficio	-189.848
Empleados	137
EBITDA	-32M

Recomendaciones
By TipRanks
Recomendaciones	Comprar
Estimación a 12 meses	+52.67 upside

Dividendos
By Dow Jones
Próximas Ganancias	5 nov 2024

Estadísticas de Mercado
By TradingEconomics
Capitalización de Mercado	-20M 230M
Apertura anterior	5.1
Cierre anterior	1.25

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

1.24 / 1.31 Soporte y Resistencia

Nektar Therapeutics Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

14 sept 2024, 01:45 UTC

Ganancias

Preview -- Barron's

13 sept 2024, 20:03 UTC

Principales Noticias

Walgreens to Pay $106.8 Million Over Alleged Fraudulent Healthcare Billings

15 sept 2024, 23:47 UTC

Charlas de Mercado

Gold Edges Higher Amid Mild Dollar Weakness -- Market Talk

15 sept 2024, 23:03 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

15 sept 2024, 23:03 UTC

Charlas de Mercado

Australian Bond Traders Watchful as Fed Easing Nears -- Market Talk

15 sept 2024, 16:52 UTC

Principales Noticias

Boeing Machinist Strike Adds Cash Crunch to New CEO's Rescue Mission -- WSJ

15 sept 2024, 09:30 UTC

Principales Noticias

Interest Rates Are Too High. The Fed Should Cut by a Half Point. -- WSJ

15 sept 2024, 07:00 UTC

Principales Noticias

World's Biggest Hedge Fund Sells Apple, Eli Lilly Stock, and Buys Microsoft, Moderna -- Barrons.com

14 sept 2024, 14:09 UTC

Principales Noticias

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- Update 1 -- WSJ

14 sept 2024, 13:25 UTC

Principales Noticias

Disney, DirecTV Reach Deal, Ending Blackout of ABC, ESPN -- WSJ

14 sept 2024, 09:30 UTC

Principales Noticias

Why a Fed Rate Cut Won't Solve the Housing Wealth Gap -- WSJ

14 sept 2024, 09:30 UTC

Principales Noticias

Americans Are Falling Behind on Their Bills. Wall Street Is Alarmed. -- WSJ

14 sept 2024, 03:00 UTC

Principales Noticias

What Scared Ford's CEO in China -- WSJ

14 sept 2024, 03:00 UTC

Principales Noticias

What Scared Ford's CEO in China -- WSJ -2-

14 sept 2024, 00:01 UTC

Principales Noticias

Why 96% of Boeing's Machinists Voted to Go on Strike -- Update

13 sept 2024, 21:14 UTC

Principales Noticias

Why 96% of Boeing's Machinists Voted to Go on Strike -- WSJ

13 sept 2024, 21:06 UTC

Principales Noticias

Starliner Astronauts Say NASA Ran Short of Time to Test Boeing Craft -- WSJ

13 sept 2024, 20:50 UTC

Charlas de Mercado

Financial Services Roundup: Market Talk

13 sept 2024, 20:47 UTC

Charlas de Mercado

Saudi Arabia Credit Outlook Raised to Positive on Economic Investments -- Market Talk

13 sept 2024, 20:44 UTC

Adquisiciones, fusiones, absorciones

Schlumberger Stock Was Once as Hot as Nvidia. Why It's a Buy. -- Barrons.com

13 sept 2024, 20:41 UTC

Principales Noticias

Berkshire Hathaway's Stock Is So Rich Even Berkshire Is Buying Less of It -- Update

13 sept 2024, 20:31 UTC

Ganancias

These Stocks Moved the Most Today: Adobe, Boeing, Trump Media, Oracle, Uber, RH, Moderna, Etsy, and More -- Barrons.com

13 sept 2024, 20:13 UTC

Adquisiciones, fusiones, absorciones

BlackRock: Expects to Close Previously Announced Acquisition of Global Infrastructure Partners on Oct 1 >BLK

13 sept 2024, 20:10 UTC

Adquisiciones, fusiones, absorciones

BlackRock Announces Expected Closing Date For Acquisition Of Global Infrastructure Partners >BLK

13 sept 2024, 20:02 UTC

Adquisiciones, fusiones, absorciones

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept 2024, 20:02 UTC

Adquisiciones, fusiones, absorciones

CGI Completes Acquisition Of Aeyon, Expands Capabilities For National Security And Civilian Agency Missions >GIB

13 sept 2024, 19:44 UTC

Charlas de Mercado

Treasury Yields Fall as Odds of 50bp Fed Cut Rise -- Market Talk

13 sept 2024, 19:20 UTC

Charlas de Mercado

Crude-Oil Futures End Week With Small Gains -- Market Talk

13 sept 2024, 19:09 UTC

Charlas de Mercado

U.S. Natural-Gas Futures Post Weekly Gain -- Market Talk

13 sept 2024, 18:01 UTC

Charlas de Mercado

Gold Analysts Call For New Leg Of Rally -- Market Talk

Comparación entre iguales

Cambio de precio

Nektar Therapeutics Esperado

Precio Objetivo

By TipRanks

52.67% repunte

Estimación a 12 meses

Media 2 USD 52.67%

Máximo 2 USD

Mínimo 2 USD

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Nektar Therapeutics Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

Comprar

Mantener

Vender

De acuerdo con 2 analistas que ofrecen calificaciones bursátiles a para Nektar Therapeutics Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.24 / 1.31Soporte y Resistencia

Recent bullish events outweigh bearish events.

There is one bullish event.

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.